Abiopharma

🔍 Walbert Keli (Director)

Company: Apellis Pharmaceuticals, Inc. (APLS)

Report Date: 2026-01-01

Detailed Transactions and Holdings:

• Acquired 7,961 shares of Common Stock (Direct)
  Date: 2026-01-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 17,051.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 14,684 shares of Stock Option (Right to Buy) at $25.12 per share (Derivative)
  Date: 2026-01-01 | Code: A | Expires: 2033-12-31 | equity_swap_involved: 0 | shares_owned_after: 14,684.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: This restricted stock unit was granted on January 1, 2026. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election.
• F2: This option was granted on January 1, 2026. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant.